Tharimmune, Inc.

NasdaqCM THAR

Tharimmune, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD -11.00 M

Tharimmune, Inc. EBIT is USD -11.00 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -25.33% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.
  • Tharimmune, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -8.77 M, a -226.17% change year over year.
  • Tharimmune, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -2.69 M, a 40.45% change year over year.
  • Tharimmune, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -4.52 M.
Key data
Date EBIT EBITDA Net Income EPS (Diluted)
Market news
NasdaqCM: THAR

Tharimmune, Inc.

CEO Mr. Randy D. Milby MBA
IPO Date Jan. 12, 2022
Location United States
Headquarters 1200 Route 22 East
Employees 2
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

StockViz Staff

January 15, 2025

Any question? Send us an email